胆碱能性荨麻疹临床评估工具的开发及应用进展

doi:10.35541/cjd.20220400

Abstract

Abstract: 【Abstract】 This review comprehensively summarizes clinical assessment tools which have been developed and validated for cholinergic urticaria （CholU）, involving diagnosis and severity assessment of CholU, assessment of patients′ quality of life, and assessment of disease control. The application methods and status of relevant tools in clinical practice are introduced in detail.

Key words: Urticaria, Diagnosis, Disease management, Assessment tools, Cholinergic urticaria

Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria[J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566.doi:10.35541/cjd.20220400

References ［29］

［1］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all.15090.
［2］	Park HJ, Montgomery JR, Boggs NA. Anaphylaxis after the Covid⁃19 vaccine in a patient with cholinergic urticaria［J］. Mil Med, 2021:usab138. doi: 10.1093/milmed/usab138.
［3］	Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias ⁃ The EAACI/GA2 LEN/EDF/UNEV consensus recommendations 2016 update and revision［J］. Allergy, 2016,71（6）:780⁃802. doi: 10.1111/all.12884.
［4］	Altrichter S, Salow J, Ardelean E, et al. Development of a standardized pulse⁃controlled ergometry test for diagnosing and investigating cholinergic urticaria［J］. J Dermatol Sci, 2014,75（2）:88⁃93. doi: 10.1016/j.jdermsci.2014.04.007.
［5］	Altrichter S, Wang Y, Schumacher P, et al. Acetylcholine⁃induced whealing in cholinergic urticaria ⁃ what does it tell us?［J］. J Dermatol Sci, 2021,103（1）:10⁃15. doi: 10.1016/j.jdermsci.2021. 05.001.
［6］	Fukunaga A, Washio K, Hatakeyama M, et al. Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management［J］. Clin Auton Res, 2018,28（1）:103⁃113. doi: 10.1007/s10286⁃017⁃0418⁃6.
［7］	Altrichter S, Schumacher P, Alraboni O, et al. Sensitization against skin resident fungi is associated with atopy in cholinergic urticaria patients［J］. Clin Transl Allergy, 2020,10:18. doi: 10.1186/s13601⁃020⁃00324⁃z.
［8］	Kim JE, Jung KH, Cho HH, et al. The significance of hypersensitivity to autologous sweat and serum in cholinergic urticaria: cholinergic urticaria may have different subtypes［J］. Int J Dermatol, 2015,54（7）:771⁃777. doi: 10.1111/ijd.12549.
［9］	Kaur I, Jakhar D. Starch⁃iodine test viewed through a dermoscope［J］. J Am Acad Dermatol, 2020,83（1）:e11⁃e12. doi: 10.1016/j.jaad.2019.08.008.
［10］	Koch K, Weller K, Werner A, et al. Antihistamine updosing reduces disease activity in patients with difficult⁃to⁃treat cholinergic urticaria［J］. J Allergy Clin Immunol, 2016,138（5）:1483⁃1485.e9. doi: 10.1016/j.jaci.2016.05.026.
［11］	Ruft J, Asady A, Staubach P, et al. Development and validation of the Cholinergic Urticaria Quality⁃of⁃Life Questionnaire （CholU⁃QoL）［J］. Clin Exp Allergy, 2018,48（4）:433⁃444. doi: 10.1111/cea.13102.
［12］	Mizuno M, Fukunaga A, Washio K, et al. A visual analogue scale for itch and pain in 23 cases of cholinergic urticaria［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:e493⁃e495. doi: 10.1111/jdv.16410.
［13］	Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire （CU⁃QoL）［J］. Allergy, 2005,60（8）:1073⁃1078. doi: 10.1111/j.1398⁃9995.2005.00833.x.
［14］	Maurer M, Zuberbier T, Metz M. The classification, pathogenesis, diagnostic workup, and management of urticaria: an update［J］. Handb Exp Pharmacol, 2022,268:117⁃133. doi: 10.1007/164_2021_506.
［15］	于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷（CU⁃Q2oL）信效度验证［J］. 中华皮肤科杂志, 2020,53（12）:992⁃997. doi: 10.35541/cjd.20200091.
［16］	Zhao Z, Zhang C, Jiang Y, et al. Chinese version of the chronic urticaria quality of life questionnaire: cultural adaptation, factor analysis, assessment of reliability and validity［J］. Arch Dermatol Res, 2021［2022⁃06⁃01］. doi: 10.1007/s00403⁃021⁃02300⁃4.
［17］	Baiardini I, Braido F, Molinengo G, et al. Chronic Urticaria Patient Perspective （CUPP）: the first validated tool for assessing quality of life in clinical practice［J］. J Allergy Clin Immunol Pract, 2018,6（1）:208⁃218. doi: 10.1016/j.jaip.2017.06.023.
［18］	Finlay AY, Khan GK. Dermatology Life Quality Index （DLQI）⁃⁃a simple practical measure for routine clinical use［J］. Clin Exp Dermatol, 1994,19（3）:210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x.
［19］	Ghazanfar MN, Holm JG, Thomsen SF. Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature［J］. Dermatol Ther, 2020,33（6）:e14010. doi: 10.1111/dth.14010.
［20］	Maurer M, Giménez⁃Arnau A, Ensina LF, et al. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2⁃year results［J］. World Allergy Organ J, 2020,13（9）:100460. doi: 10.1016/j.waojou.2020.100460.
［21］	Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient⁃reported outcome instrument for assessing urticaria control［J］. J Allergy Clin Immunol, 2014,133（5）:1365⁃1372. doi: 10.1016/j.jaci.2013. 12.1076.
［22］	Nakatani S, Oda Y, Washio K, et al. The Urticaria Control Test and Urticaria Activity Score correlate with quality of life in adult Japanese patients with chronic spontaneous urticaria［J］. Allergol Int, 2019,68（2）:279⁃281. doi: 10.1016/j.alit.2018.11.003.
［23］	García⁃Díez I, Curto⁃Barredo L, Weller K, et al. Cross⁃cultural adaptation of the Urticaria Control Test from German to Castilian Spanish［J］. Actas Dermosifiliogr, 2015,106（9）:746⁃752. doi: 10. 1016/j.ad.2015.05.009.
［24］	Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Validity, reliability and interpretability of the Thai version of the urticaria control test （UCT）［J］. Health Qual Life Outcomes, 2016,14:61. doi: 10.1186/s12955⁃016⁃0466⁃y.
［25］	Lee JH, Bae YJ, Lee SH, et al. Adaptation and validation of the Korean version of the Urticaria Control Test and its correlation with salivary cortisone［J］. Allergy Asthma Immunol Res, 2019,11（1）:55⁃67. doi: 10.4168/aair.2019.11.1.55.
［26］	Kocatürk E, Kızıltaç U, Can P, et al. Validation of the Turkish version of the Urticaria Control Test: correlation with other tools and comparison between spontaneous and inducible chronic urticaria［J］. World Allergy Organ J, 2019,12（1）:100009. doi: 10.1016/j.waojou.2018.11.007.
［27］	Khoshkhui M, Weller K, Fadaee J, et al. Evaluation of the reliability and validity of the Persian version of Urticaria Control Test （UCT）［J］. Iran J Allergy Asthma Immunol, 2021,20（4）:423⁃431.
［28］	Dortas Junior SD, Valle S, Weller K, et al. Validity, reliability, and interpretability of the Brazilian urticaria control test［J］. Allergy Asthma Proc, 2020,41（3）:e61⁃e66. doi: 10.2500/aap.2020. 41.200003.
［29］	于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证［J］. 中华皮肤科杂志, 2020,53（7）:533⁃538. doi: 10. 35541/cjd.20191190.

[1]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.
[2]	Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.
[3]	Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on treat-to-target in chronic spontaneous urticaria （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 489-495.
[4]	Jiao Qingqing, Zhang Xiaoyan, Ji Jiang. Biological indicators related to disease activity of chronic spontaneous urticaria: an update [J]. Chinese Journal of Dermatology, 2023, 56(6): 559-562.
[5]	Mi Shuhong, Yu Yanqin, Hao Jinqi, Li Wei, Zhang Yang, Jia Ximei, Huang Yuxian, Sun Huaiyu, Shi Jihai. Analysis of imaging characteristics of papulopustular rosacea by high-frequency ultrasound combined with color Doppler flow imaging [J]. Chinese Journal of Dermatology, 2023, 56(6): 540-544.
[6]	Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558.
[7]	Zhang Liming, Xiao Ting. Update of the autoimmune pathogenesis of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 567-570.
[8]	Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524.
[9]	Chen Qiquan, Kong Minmin, Yang Xianjie, Wang Huan, Li Jian, Zhang Mingwang, Song Zhiqiang. Clinical analysis of allergen reactivity and atopic disease history in 168 patients with chronic inducible urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 496-503.
[10]	Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517.
[11]	Wang Xin, Liu Lijuan, Li Linfeng. Clinical features of chronic spontaneous urticaria in China: results from a hospital-based multicenter epidemiological survey [J]. Chinese Journal of Dermatology, 2023, 56(6): 525-530.
[12]	Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511.
[13]	Hu Qingjie, Zhou Min, Yao Xu. Analysis of clinical characteristics of 36 patients with pyoderma gangrenosum and comparison between the PARACELSUS score and Delphi criteria for their diagnosis [J]. Chinese Journal of Dermatology, 2023, 56(5): 410-414.
[14]	Committee on Sexually Transmitted Diseases, China Dermatologist Association. Expert consensus on clinical management of serofast state in syphilis （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 383-388.
[15]	Jia Weixue, Li Chengrang. Comparison of Chinese and international guidelines and consensus for the diagnosis and treatment of vitiligo [J]. Chinese Journal of Dermatology, 2023, 56(5): 471-475.

Development and application of clinical assessment tools for cholinergic urticaria

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［29］

Related Articles 15

Metrics

Comments

Recommended 10